ABSTRACT
Renal cell carcinoma (RCC) is a prevalent and aggressive tumor of the urinary system with limited treatment success and poor patient outcomes. However, some patients exhibit long-term symptom relief and are considered ’cured’ after successful treatment. This study explores the genetic and pathway mechanisms underlying RCC cure for the first time, utilizing a survival model called the 3-parameter defective Gompertz cure model.
The study methodology involved two main steps: Firstly, employing Weighted Gene Co-expression Network Analysis (WGCNA) for gene network analysis, which identified six key modules associated with different aspects of cancer progression and survival. Hub genes, pivotal in cellular interactions, were pinpointed through network analysis. Secondly, the 3-parameter defective Gompertz model was utilized to identify therapeutic genes linked to successful treatment outcomes (CSRGs) in RCC. These genes were then compared with genes associated with patient survival (SRGs) using a cox model.
The study found ten hub genes commonly identified by both the defective 3-parameter Gompertz and Cox models, with six genes (NCAPG, TTK, DLGAP5, TOP2A, BUB1B, and BUB1) showing strong predictive values. Moreover, six hub genes (TTK, KIF20A, DLGAP5, BUB1, AURKB, and CDC45) were highlighted by the defective Gompertz model as significantly impacting cure when expressed at high levels. Targeting these hub genes may hold promise for improving RCC treatment outcomes and prognosis prediction.
Overall, this study provides valuable insights into the molecular mechanisms of RCC and underscores the potential of the defective 3-parameter Gompertz model in guiding targeted therapeutic approaches.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
title and abstract edited. figures 10 and 12 edited. manuscript text edited.
Data Availability
All data produced are available online at: Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/)
